BIOPHARMA® :  Biosimilars/Biobetters Pipeline Database
    New!  The most comprehensive follow-on biopharmaceuticals (biosimilars, biobetters and biogenerics) pipeline reference. 
    Deep discount for do-it-yourself early adopters (you run the database on your PC)

    • Find competing products and companies; product/API licensing sources; collaborators and partners; licensees/customers for your products, technologies, services and equipment
    • Over 1,200 product records:  >650 biosimilars, >450 biobetters; plus >550 involved company records
    • From the author of BIOPHARMA:  Biopharmaceuticals in the U.S. and European Markets, the only information resource specializing in biopharmaceuticals ("The Reference Products' Reference") online at www.biopharma.com 
    • Incredible low price - $375 (only $.30/pipeline product record) for 1-time database purchase (with future updates discounted for early adopters) - Compare with all other pipeline data sources and market studies!
    • BIOPHARMA Bundle:  Combine pipeline database 1-time purchase with a 1-year online BIOPHARMA subscription for $900, an unbeatable low price.  Essential for biosimilar developers, e.g., BIOPHARMA includes patent/data/market exclusivity expirations for >130 reference products and much unique bioprocessing, regulatory, patent, licensing and other critical information published nowhere else.
    • Satisfaction guaranteed!  Full refund within 1 month, e.g., if you do not learn information that critically affects your company.

    Further Information/Flyer
    Users Guide
    Sample product records
    Order/inquiry form
    Beta testing partial records database online: Click on "Go"           or enter password for full accesss

    Some top level data are presented below. 
    For further information, please contact the author. 

Biosimilars/Biobetters Pipeline Database - Top Level Data (6/16/2014)

  • total product entries = 1241
  • biosimilars = 655
  • biobetters = 452
  • total pipeline products (biosimilars + biobetters) = 1107
  • ref. products = 132
  • biogenerics (in dev. countries) = <200 (counted as biosimilars)
The database only covers recombinant proteins and a few other protein products. Vaccines, blood-derived, cultured cells and tissues and other types of biologics are not included!  US/EU-marketed reference products lacking any known biosimilars or biobetters in development are also excluded.  Biosimilar and biobetter U.S. and EU launchable dates (patent expiration and data and market exclusivity expirations) are reported for all >130 reference products are reported in BIOPHARMA, "The Reference Products Reference."
    Note, nearly 200 "biogenerics" in lesser-regulated countries are classed at this top level as biosimilars, but even ignoring these, over 450 biosimilars in the pipeline are reported.

Near-term economic impact includes over 40, nearly all recombinant, mostly monoclonal antibody, products with over $1 billion/year sales, and about 20 others with sales over $500 million/year. 

Follow-on products containing rather (bio)similar active agents are classed as either biosimilar (much the same, including approvable as biosimilars) or biobetter (too different to be approved as a biosimilar).  There are still relatively few genuine biosimilars (by US/EU standards), i.e., products approved by a formal biosimilar mechanism, mostly those in Europe.  Biogenerics are the subset of biosimilars primarily oriented to lesser-regulated, developing country markets.  The great majority of biogenerics are currently marketeted internationally, with their pipeline rather small compared to major market-oriented biosimilars.


Note, multiple companies can be involved with each product.

Some Popular Targeted Reference Products
[No. of biosimilars by reference product]
Humira 20
Remicade 13
Epoetin alfa 82
Neupogen 56
Neulasta 20
Enbrel 26
Rituxan 43
Herceptin 37
Lantus 7
Avastin 21
Insulin and analogs 47
Interferons (alfa) 66
Interferons (beta) 26
Somatropins 33
Cancer indications 380
mAbs, mAb fragments      215

Companies With the Largest Biosimilars and Biobetters Pipelines
Biosimilars (10 or more)
Harvest Moon Pharmaceuticals USA, Inc. 28
BioXpress Therapeutics S.A. 19
Zydus Cadilla Healthcare Ltd. 17
Biocon Ltd. 17
Mylan Labs. 14
Inbiopro Solutions Pvt Ltd. 14
Creative Biomart Inc. 13
Green Cross Corp. 12
Bio Sidus S.A. 12
AXXO GmbH 12
Dong-A Pharmaceutical. 12
Bioton S.A.. 11
Chemo Group (Grupo Insud ) 11
Novartis AG 10
LG Life Sciences Ltd. 10
Amega Biotech 10
Cassara Biotech 10
Biobetters (7 or more)
Novo Nordisk A/S 18
Biogen Idec 14
Lilly, Eli & Co. 13
Bolder BioTechnology, Inc. 12
Roche/Genentech 12
Merck KGaA 10
PROLOR Biotech, Inc. 9
Baxter 8
Pfizer Inc. 8
Flamel Technologies 7

Contact information:

Copyright©2014. Part of the BIOPHARMA® (registered U.S. trademark) suite of biopharmaceutical information products/services.

Biosimilarspipeline.com Information Resources [available and planned]

1 Year and No Response from FDA!  Citizen Petition filed with FDA:  Biologics Nomenclature and Public Information:  Suitably Descriptive Names/Identifiers and Public Disclosures are Needed

Related articles by the Webmaster:

Need a Consultant With Biosimilars Expertise? - The Web master, Ronald A. Rader, is available.  See his short bio and full resume. Mr. Rader is the author of BIOPHARMA, the only information resource/reference specializing in biopharmaceuticals (see www.biopharma.com), has authored the defining articles concerning biopharmaceuticals and biosimilars/FOBs (e.g., see the "What is...", "(Re)Defining" and related abstracts/links above), and is a world-class expert concerning biopharmaceutical information, products, techologies, and related market, technology and policy assessments. 
Sponsors needed!   Without financing and/or collaboration with a view towards the long term, we (Biotech. Info. Inst.) do not foresee commercial viability for our solely developing biosimilar information resources. There simply are too few involved with too few opportunities for cost-recovery, much less profit; and there are no plans to devalue this site by taking advertising. Thus, corporate or other funding or collaboration is needed. We envision developing the best (or only) Web site/database/reference providing substantive authoritive, including (bio)technical, information about biosimilars (and biobetters and biogenerics). To learn more, contact biotech@biopharma.comRon Rader.